Engineers at the University of Pennsylvania reported a lipid nanoparticle (LNP) platform that reverses T‑cell exhaustion in solid tumors and drives durable tumor control in preclinical models, presenting a potential universal immunotherapy adjunct. Separately, Penn researchers and collaborators modified ionizable lipid chemistry to reprogram dendritic cell metabolism, enhancing mRNA vaccine potency while lowering inflammatory side effects in mice and human cell assays. The immunotherapy LNPs focused on metabolic and transcriptional rewiring of exhausted tumor‑infiltrating lymphocytes, whereas the vaccine LNP work introduced crosslinking imidoester chemistry to shift dendritic cell glycolysis and improve antigen presentation. Both lines of work show that nanoparticle chemistry can modulate immune cell function beyond payload delivery. Taken together, the studies expand LNP design from passive carriers to active immunomodulators—relevant for cancer immunotherapy, vaccine development and next‑generation mRNA therapeutics. Safety profiling and clinical translation pathways will determine how quickly these advances enter trials.